C

CTI Biopharma Corp
F:CEPS

Watchlist Manager
CTI Biopharma Corp
F:CEPS
Watchlist
Price: 28 EUR Market Closed
Market Cap: 3.7B EUR

Relative Value

There is not enough data to reliably calculate the relative value of CEPS.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CEPS Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
53
Median 5Y
50.7
Industry
7.8
vs History
vs Industry
Median 3Y
-58
Median 5Y
-17.2
Industry
24.1
vs History
vs Industry
Median 3Y
-48.8
Median 5Y
-14.5
Industry
21.8
vs History
vs Industry
Median 3Y
-48.6
Median 5Y
-27.5
Industry
23.8
vs History
vs Industry
Median 3Y
-158.4
Median 5Y
-139.1
Industry
3.3
vs History
vs Industry
Median 3Y
53.1
Median 5Y
51
Industry
8
vs History
vs Industry
Median 3Y
56.4
Median 5Y
54.9
Industry
10.3
vs History
vs Industry
Median 3Y
-77.7
Median 5Y
-23.2
Industry
6.3
vs History
vs Industry
Median 3Y
-74.6
Median 5Y
-22.2
Industry
6.7
vs History
vs Industry
Median 3Y
-48.9
Median 5Y
-14.6
Industry
7.9
vs History
vs Industry
Median 3Y
-48.9
Median 5Y
-14.6
Industry
6.3
vs History
vs Industry
Median 3Y
78.6
Median 5Y
57.6
Industry
5.5

Multiples Across Competitors

CEPS Competitors Multiples
CTI Biopharma Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
CTI Biopharma Corp
F:CEPS
3.7B EUR 57.5 -62.9 -84.3 -81
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 623 419.7 -159 807.1 -194 056.8 -191 842.4
US
Abbvie Inc
NYSE:ABBV
406.3B USD 6.8 173 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.7B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
156.1B USD 5.4 19.2 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 095.2 -534.6 -582.2 -566.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.6B USD 16.4 1 207.2 162.8 197.4
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.3 59.9
P/E Multiple
Earnings Growth PEG
US
C
CTI Biopharma Corp
F:CEPS
Average P/E: 190.9
Negative Multiple: -62.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 807.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 207.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
CTI Biopharma Corp
F:CEPS
Average EV/EBITDA: 40.3
Negative Multiple: -84.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 056.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -582.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.8
N/A N/A
NL
argenx SE
XBRU:ARGX
58.3
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
CTI Biopharma Corp
F:CEPS
Average EV/EBIT: 46.5
Negative Multiple: -81
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 842.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.4
N/A N/A
NL
argenx SE
XBRU:ARGX
59.9
N/A N/A